Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart + Trifluridine/Tipiracil + Bevacizumab in Refractory mCRC
NCT06873763Phase 2Recruiting
- Sponsor
- STCube
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelmastobart in colorectal cancer (CRC), sponsored by STCube. Primary endpoints: Incidence of Dose Limiting Toxicity up to 6 months, Recommended Phase 2 Dose up to 2 years and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
nelmastobart
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06873763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873763.